High-dose chemotherapy for solid tumors: results of the EBMT

Crit Rev Oncol Hematol. 2002 Feb;41(2):129-40. doi: 10.1016/s1040-8428(01)00150-0.

Abstract

The European Group for Blood and Marrow Transplantation (EBMT), formerly known as European Group for Bone Marrow Transplantation, was established in 1974 in the Netherlands to share experiences, to promote research and clinical studies and to set up registries in the field of hematopoietic tissue transplantation. At the present time more 400 European and non-European centers are members of the EBMT group. In 1984 a new Working Party was created (Solid Tumors) with the aim to investigate the role of high-dose chemotherapy and stem cell support in the fields of adult and pediatric solid tumors. By January 2000 more than 14000 patients were registered, and at the present time this Registry is the world largest database on this subject. Several phase III randomized clinical trials have recently started on behalf of the Group in different diseases (breast carcinoma, small cell lung cancer, ovarian carcinoma, germ cell tumors and Ewing's family sarcoma). Hundreds of randomized patients will finally produce clearer information on this still experimental therapeutic modality. This paper will describe the EBMT Solid Tumors Working Party Registry updated results as well as the main ongoing studies.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Female
  • Humans
  • Male
  • Neoplasms / drug therapy*
  • Randomized Controlled Trials as Topic

Substances

  • Antineoplastic Agents